http://purl.org/np/RAvmD3DOc4... RAvmD3DOc4

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasAttributedTo wasAttributedTo

https://orcid.org/0000-0002-3668-2627 Elif Ozkan

Elif Ozkan

2022-10-11T09:43:22.630Z

http://purl.org/np/RAvmD3DOc4... RAvmD3DOc4

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#generatedAtTime generatedAtTime

2022-10-11T09:43:22.630727

Elif Ozkan

2022-10-11T09:43:22.630Z

http://purl.org/np/RAvmD3DOc4... RAvmD3DOc4

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasQuotedFrom wasQuotedFrom

Ivabradine is indicated by the FDA to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure. It is also indicated for treatment of stable symptomatic heart failure as a result of dilated cardiomyopathy for pediatric patients 6 months of age or more. The drug is indicated for patients with left ventricular ejection fraction of less than 35%.

Elif Ozkan

2022-10-11T09:43:22.630Z